Singapore’s Health Sciences Authority (HSA) has awarded conditional approval for Gilead Sciences Singapore’s experimental antiviral drug remdesivir, under the brand name Veklury, to treat adults with Covid-19.

The drug is indicated for patients with oxygen saturation less than or equal to 94%, as well as those who need supplemental oxygen or intensive breathing support, including invasive mechanical ventilation.

HSA is collaborating with the Ministry of Health to identify the subcategory of patients who could benefit from this drug.

In a statement, HSA said: “To optimise the use of remdesivir in Covid-19 management, HSA is working with the Ministry of Health and relevant experts to further define the subcategory of patients who are likely to benefit most from this medicine.

“Although the data on its efficacy and safety is very limited at this point in time, HSA has expedited the review of remdesivir given the urgent public health need during the Covid-19 pandemic.”

Under the terms of the conditional approval, Gilead has to collect more safety data and monitor the use of remdesivir in this indication. HSA also asked the company to submit data from ongoing clinical studies to ensure the continued safety and efficacy of the drug.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

HSA allowed early access to remdesivir for Covid-19 patients in Singapore since March this year. Gilead filed for registration of the drug in Singapore on 22 May and secured the conditional approval on 10 June.

In May, Gilead received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) and exceptional approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for remdesivir to treat Covid-19.